In
Intercept (Alfasigma)
New York NYFounded 2002500 employees
Private CapbiotechAcquiredHepatology
Platform: Ocaliva PBC
Market Cap
N/A
All Drugs
4
Clinical Trials
5
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Polafutibatinib | INT-7771 | Preclinical | 1 | PLK4 | NASH | ||
| Tiralucimab | INT-5851 | NDA/BLA | 1 | CDK2 | MDS | ||
| INT-3699 | INT-3699 | Preclinical | 1 | GPRC5D | AngelmanHeart Failure | ||
| INT-9034 | INT-9034 | Phase 1/2 | 2 | Menin | NASH |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)